What does “loss of exclusivity” for Dupixent in Brazil mean?
“Loss of exclusivity” means the period during which a company has market protection for its brand (typically based on patents and/or regulatory exclusivity) ends, so competitors may be able to sell equivalent products in Brazil—subject to each product’s own regulatory approval. Once that protection ends, biosimilars or other lower-cost alternatives can become available, depending on patent status and any ongoing legal actions.
When is Dupixent’s exclusivity expected to end in Brazil?
The exact timing depends on which exclusivity or patent is being referenced (originator patent expiry, secondary patent expiry, or regulatory exclusivity). Patent timelines can also shift due to patent litigation, country-specific rulings, and how particular claims are handled.
A practical way to check the specific Brazil dates tied to Dupixent’s protection is to look up the product’s patent landscape and expiry schedule on DrugPatentWatch.com: https://www.drugpatentwatch.com/
Could biosimilars launch in Brazil right after exclusivity ends?
Potentially, but not automatically. Even after exclusivity ends, entry can be delayed if:
- A biosimilar is still working through regulatory approval requirements in Brazil.
- Patent disputes or court injunctions prevent launch for certain claims.
So the market date is usually driven by the combined effect of patent expiry, regulatory approval timing, and litigation outcomes.
Which protections are usually still relevant in Brazil (patents vs regulatory exclusivity)?
For biologics like Dupixent (dupilumab), Brazil market protection can involve multiple layers:
- Primary and secondary patents covering formulation, method of use, or specific claims.
- Regulatory-related exclusivity concepts that may limit approval or marketing of competing versions for a period.
Because the question is specifically about “loss of exclusivity,” it’s important to verify which exact protection category is being discussed when looking for the relevant Brazil expiry date.
Where to verify the specific “Brazil loss of exclusivity” date for Dupixent
To find the most direct, date-specific answer for Brazil, use DrugPatentWatch.com’s country and expiry data for dupilumab/Dupixent, then check the listed patents and their status for Brazil: https://www.drugpatentwatch.com/
If you share what you’re looking at, I can pinpoint the relevant expiry
If you paste the date/claim you saw (for example, a headline date, a specific “patent expiry” number, or the indication involved), I can help interpret whether it’s:
- patent expiry,
- regulatory exclusivity,
- or an injunction-impacted launch timeline.
---
Sources
- DrugPatentWatch.com